Hypha Labs Inc., previously known as Digipath Inc. following the sale of its cannabis lab assets, has appointed Craig Ellins as its Chief Science Officer. The company has been at the forefront of developing innovative technology that focuses on new methods of producing active ingredients found in functional mushrooms like psilocybin, using its patent-pending bioreactor design.
Ellins is described by the company as a forward-thinker in emerging technologies and industries. With a background in founding and leading companies such as One World Pharma and GB Sciences, he brings a wealth of experience in identifying and seizing early-stage opportunities in new markets. His deep knowledge and understanding of the cannabis industry is seen as particularly valuable by Hypha Labs, as they believe the psilocybin sector will evolve similarly.
The appointment of Ellins as Chief Science Officer signifies Hypha Labs’ commitment to pushing the boundaries of innovation in the production of active ingredients found in functional mushrooms. His expertise and leadership in emerging markets are expected to drive the company’s success in this new and evolving industry landscape.